Although the prognosis for ovarian cancer patients has improved in recent years, it is still the most lethal gynecologic tumor [1, 2]. In a video interview, gynecologist Prof. Andreas Günthert, MD, and oncologist Dr. Désirée Gassmann, MD, give their assessment of the current situation of patients with ovarian cancer, also highlighting the impact of the Covid-19 pandemic.
In conversation: Prof. Dr. med. Andreas Günthert, specialist in gynecology and obstetrics, and Dr. med. Désirée Gassmann, specialist in general internal medicine and specialist in medical oncology from the gyn-zentrum Luzern (www.gyn-zentrum.ch)
Experience with ovarian cancer patients during the Covid-19 pandemic.
The interviews reflect the personal and independent opinions of Prof. Günthert and Dr. Gassmann. GlaxoSmithKline AG has no influence on the content.
Responsible for content and financed by GlaxoSmithKline AG, Talstr. 3 – 5, 3053 Münchenbuchsee.
Trademarks are property of their respective owners. ©2020 GSK group of companies or its licensor.
Short subject information Zejula
PM-CH-NRP-ADVR-210013-02/2021
Literature
1. Wu, J., et al, Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983-2012. J Cancer, 2018. 9(19): p. 3548-3556.
2. Buechel, M., et al, Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol, 2019. 30(5): p. 721-732.
